According to Evolent Health's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.71776. At the end of 2023 the company had a P/S ratio of 1.93.
Year | P/S ratio | Change |
---|---|---|
2023 | 1.93 | -8% |
2022 | 2.10 | -22.87% |
2021 | 2.72 | 91.43% |
2020 | 1.42 | 57.37% |
2019 | 0.9045 | -64.09% |
2018 | 2.52 | 19.26% |
2017 | 2.11 | -31.01% |
2016 | 3.06 | -40.98% |
2015 | 5.19 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
National Healthcare
NHC | 1.19 | -30.94% | ๐บ๐ธ USA |
Global Cord Blood CORBF | 0.8635 | -49.73% | ๐ญ๐ฐ Hong Kong |
Graham Holdings GHC | 0.7048 | -58.97% | ๐บ๐ธ USA |
CryoLife CRY | N/A | N/A | ๐บ๐ธ USA |